A better buy-in window may exist right now for Lexicon Pharmaceuticals Inc. (LXRX)

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) stock fell -26.61% on Friday to $2.40 against a previous-day closing price of $3.27. With 7.13 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.24 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.7100 whereas the lowest price it dropped to was $2.3900. The 52-week range on LXRX shows that it touched its highest point at $6.33 and its lowest point at $1.31 during that stretch. It currently has a 1-year price target of $20.00. Beta for the stock currently stands at 1.63.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LXRX was down-trending over the past week, with a drop of -24.53%, but this was up by 11.63% over a month. Three-month performance surged to 27.66% while six-month performance fell -21.57%. The stock lost -32.39% in the past year, while it has lost -39.09% so far this year. A look at the trailing 12-month EPS for LXRX yields -0.61 with Next year EPS estimates of -0.37. For the next quarter, that number is -0.16. This implies an EPS growth rate of -14.00% for this year and 12.90% for next year.

Float and Shares Shorts:

At present, 149.15 million LXRX shares are outstanding with a float of 143.38 million shares on hand for trading. On Apr 28, 2022, short shares totaled 5.32 million, which was 3.56% higher than short shares on Mar 30, 2022. In addition to Mr. Lonnel Coats as the firm’s CEO & Director, Mr. Jeffrey L. Wade J.D. serves as its Pres & CFO.

Institutional Ownership:

Through their ownership of 83.82% of LXRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.62% of LXRX, in contrast to 69.44% held by mutual funds. Shares owned by individuals account for 51.95%. As the largest shareholder in LXRX with 47.58% of the stake, Invus Public Equities Advisors LL holds 71,178,364 shares worth 71,178,364. A second-largest stockholder of LXRX, BVF Partners LP, holds 14,356,589 shares, controlling over 9.60% of the firm’s shares. Fidelity Management & Research Co is the third largest shareholder in LXRX, holding 5,290,549 shares or 3.54% stake. With a 1.42% stake in LXRX, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 2,121,674 shares are owned by the mutual fund manager. The Fidelity Growth Company Fund, which owns about 1.28% of LXRX stock, is the second-largest Mutual Fund holder. It holds 1,917,395 shares valued at 3.57 million. iShares Russell 2000 ETF holds 1.03% of the stake in LXRX, owning 1,536,581 shares worth 2.86 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for LXRX since 3 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With LXRX analysts setting a high price target of $20.00 and a low target of $5.00, the average target price over the next 12 months is $12.50. Based on these targets, LXRX could surge 733.33% to reach the target high and rise by 108.33% to reach the target low. Reaching the average price target will result in a growth of 420.83% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. LXRX will report FY 2022 earnings on 03/01/2023. Analysts have provided yearly estimates in a range of -$0.51 being high and -$0.64 being low. For LXRX, this leads to a yearly average estimate of -$0.59. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Lexicon Pharmaceuticals Inc. surprised analysts by $0.01 when it reported -$0.16 EPS against a consensus estimate of -$0.17. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.15 and the low estimate is -$0.16. The average estimate for the next quarter is thus -$0.16.

Summary of Insider Activity:

Insiders traded LXRX stock several times over the past three months with 7 Buys and 0 Sells. In these transactions, 28,168 shares were bought while 0 shares were sold. The number of buy transactions has increased to 28 while that of sell transactions has risen to 7 over the past year. The total number of shares bought during that period was 466,030 while 133,480 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *